Our suite of preeclampsia, prenatal, breast and gynecological cancer, and other testing has been developed in collaboration with clinical leaders in a variety of women’s health specialties to provide accurate, actionable results.
New tests launched in October - Insights
In October 2022, Mayo Clinic Laboratories announced thirty new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
New tests launched in March - Insights
In March 2022, Mayo Clinic Laboratories announced eighteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
New tests launched in May - Insights
In May 2022, Mayo Clinic Laboratories announced eighteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
Nonradioactive assay helps diagnose heparin reaction - Insights
Rajiv Pruthi, M.B.B.S., explains how Mayo Clinic Laboratories’ serotonin release assay achieves high sensitivity and specificity while avoiding the use of radioactive materials. Serotonin release testing is an important tool in the...
Novel biomarkers added to movement disorders profile - Insights
Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' expanded movement disorders panel better identifies autoimmune conditions to guide appropriate treatment.
Improving diagnosis and treatment of Helicobacter pylori - Insights
Mayo Clinic Laboratories now offers a noninvasive approach for the molecular detection of H. pylori, with results that include prediction of clarithromycin resistance delivered within 24 hours.
Melanoma panel provides more tumor information - Insights
In this test specific episode of the "Answers From the Lab" podcast, Ruifeng (Ray) Guo, M.D., Ph.D., explains how Mayo Clinic Laboratories' comprehensive melanoma panel better informs prognosis and treatment.
Comprehensive panel boosts GIST diagnosis sensitivity - Insights
Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new assay for gastrointestinal stromal tumors, or GIST. The panel covers multiple mutations, to better inform diagnosis and treatment options.
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) - Insights
Divyanshu (Div) Dubey, M.B.B.S., describes Mayo Clinic Laboratories' new diagnostic test for CIDP, or chronic inflammatory demyelinating polyneuropathy. The new test detects two antibodies — NF155 and CNTN1 — to enhance diagnosis and guide...